DOT1L and acute myeloid leukemia: Pharmacologic inhibition of DOT1L by small molecules can restore the expression of HOXA and HOXB genes, which proves that DOT1L inhibitors are potential drug candidates for targeting DNMT3A mutant AML [14, 16].